We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ONC Oncimmune Holdings Plc

-2.40 (-8.45%)
30 Nov 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.40 -8.45% 26.00 488,014 16:35:27
Bid Price Offer Price High Price Low Price Open Price
25.20 26.80 30.00 26.00 30.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 3.79M -11.39M -0.1639 -1.64 18.62M
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:45 O 25,000 26.00 GBX

Oncimmune (ONC) Latest News (5)

Oncimmune (ONC) Discussions and Chat

Oncimmune Forums and Chat

Date Time Title Posts
24/11/202314:09Oncimmune (ONC) cancer test diagnoses '80pc of tumours' early, savin283
23/1/201807:49Oncimmune (ONC) could save millions of lives2
20/2/200100:30Online Classics plc1

Add a New Thread

Oncimmune (ONC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Oncimmune (ONC) Top Chat Posts

Top Posts
Posted at 30/11/2023 08:20 by Oncimmune Daily Update
Oncimmune Holdings Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker ONC. The last closing price for Oncimmune was 28.40p.
Oncimmune currently has 69,475,000 shares in issue. The market capitalisation of Oncimmune is £18,619,300.
Oncimmune has a price to earnings ratio (PE ratio) of -1.64.
This morning ONC shares opened at 30p
Posted at 12/10/2023 07:19 by brummy_git
Encouraging new developments from IPR rich life science firm Oncimmune.

All the details here.
Posted at 31/5/2023 10:15 by eva_1989
I dont know what Trek from LSE smoking but i badly need same ;)

He thought to pump before open so that he can sell to others...

Hi R00st3R,

I think todays interims answer your questions. All good at ONC. Well actually very good!

Should be a cracking day today!

Pity some of the revs got delayed but there is a line of sight and perhaps most importantly a change in sentiment.

Wish I could buy more at this price!

Usual caveats

Posted at 31/5/2023 08:33 by brummy_git
H1'23 results out today from Oncimmune. All the details here.
Posted at 22/5/2023 08:26 by brummy_git
Very positive M&A and contract news from global immunodiagnostics group Oncimmune today.

All the details here.
Posted at 27/2/2023 07:13 by brummy_git
Final results (y/e Aug'22) out today from global immunodiagnostics firm, Oncimmune

All the details here.
Posted at 17/2/2023 08:56 by brummy_git
Terrific news today from Oncimmune, who is partnering with with Siemens Healthineers to improve the assessment of indeterminate pulmonary nodules.

All the details here.
Posted at 22/12/2022 17:12 by brummy_git
Excellent insights here from Oncimmune CEO Adam Hill - who takes me through the recent surge in new orders, £2.1m top up fund raise and strategic options for the EarlyCDT Lung division.
Posted at 20/12/2022 07:22 by brummy_git
More encouraging contract wins for leading immunodiagnostics firm, Oncimmune.

All the news and investor commentary here.
Posted at 14/12/2022 15:33 by brummy_git
Leading immunodiagnostics firm Oncimmune successfully competes a £2.1m top up fund raise. All the details & commentary here.
Posted at 05/5/2021 06:15 by someuwin
5 May 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Return of China Rights to EarlyCDT product portfolio

Enables strategic optionality to support access to the US capital markets

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group , today announces that it has successfully agreed to acquire the intellectual property (IP) and distribution rights for the EarlyCDT (R) technology in the People's Republic of China (PRC) and Hong Kong (HK) from Genostics Company Limited (Genostics), allowing the Company to pursue the optimum route to market in this important territory.

Since granting Genostics the exclusive rights to EarlyCDT products in the PRC and HK in January 2018, Oncimmune and Genostics have collaborated to develop a lung panel with superior performance in Greater China and Asia-Pacific, given the prevalence of EGFR-positive non-small cell lung cancer (NSCLC) in the region. The Asia-specific lung panel has been used in a multi-centre study, previously announced on 10 May 2019, and which is now due to complete in China in H1 2021. Data from this study are intended to be used to support approval by the China National Medical Products Administration (NMPA) for the use of the Asia-specific lung cancer test in the PRC.

Under the agreement announced today, all material, IP, data, and goodwill will be transferred back to the Company, and Oncimmune will be paid in full for the royalties due in January 2021 under the existing Technology Licencing Agreement. In consideration, Oncimmune has agreed to pay a fixed amount for the return of the IP and distribution rights, with the majority of the value of the consideration being conditional on fixed future events.

With accelerating growth of Oncimmune's ImmunoINSIGHTS business, the Company intends to explore options available to it to access the US capital markets in the near term. The termination of Oncimmune's partnership with Genostics and return of the EarlyCDT product rights to the PRC and HK markets provides Oncimmune with further strategic optionality which could support a path to the US capital markets.

As part of the agreement, and as previously announced, Genostics has agreed to a lock-in of its remaining shareholding in Oncimmune (currently 4.73 per cent. of the issued share capital) for a period of 12 months from 6 May 2021, except under certain limited exceptions.

Dr Adam M Hill, CEO of Oncimmune said: " We are grateful for the collaboration with Genostics and its parent company, Gene Group Holdings Ltd, over the past three years and are pleased with the progress that has been made with our Asia-specific lung panel. However, as both companies consider their future on different equity capital markets, the continuing success of the EarlyCDT product portfolio, both in and outside of PRC and HK, requires Oncimmune to own the IP and distribution rights. We are delighted that Genostics has agreed to continue to participate in Oncimmune's success as a shareholder, and Oncimmune looks forward to progressing its market access plans imminently."
Oncimmune share price data is direct from the London Stock Exchange

Your Recent History

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |